Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Taste Disorders 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 2068Radiotherapy 1990Cisplatin 1857Carboplatin 1560Gemcitabine 1455Paclitaxel 1322Bevacizumab 1321pembrolizumab 1240Docetaxel 1227Oxaliplatin 1184Capecitabine 1179Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 973Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 641Lenalidomide 619Biopsy 595Specimen Handling 570

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × miraculin protein, Synsepalum dulcificum × Clear all
NCT05273307 2025-09-22

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

University of California, San Francisco

Phase 3 Recruiting
40 enrolled
Head & Neck

Head and Neck Neoplasms, Taste Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡